SkyCell, a Swiss pharma-tech company manufacturing smart containers enabling the safe, secure, and sustainable transportation of pharmaceutical products, secured $34.8 million (CHF 32 million) in Series C funding.
The round, a combination of equity and debt financing, included DisruptAD (the venture capital arm of Abu Dhabi-based sovereign wealth fund ADQ), SHUAA Capital psc, and China-based and Zurich-based family offices with strategically important networks. Existing investor Mobiliar, the oldest private insurance company in Switzerland, also participated with follow-on funding.
The funding will enable Skycell to grow sales teams and convert its growing pipeline of global pharmaceutical and biotech clients. Additionally, we will be able to further improve the experience we offer our clients, further differentiate our hardware and SaaS offerings based on their needs and become their distribution solution of choice for the cold chain.
Company: SkyCell AG
Raised: $34.8M
Round: Series C
Funding Month: October 2021
Lead Investors:
Additional Investors: DisruptAD, SHUAA Capital psc, and Mobiliar
Company Website: http://www.skycell.ch/
Software Category: Temperature-controlled container solutions
About the Company: Founded in Switzerland in 2012, SkyCell designs and manufactures smart containers that allow pharmaceutical companies to predict, reduce, and control the risks associated with transporting temperature-sensitive drugs. SkyCell has also launched a SaaS solution, SECURE, that provides pharma companies with end-to-end oversight of every shipment around the world and an automated approval capability that reduces quality approval time to just minutes. Skycell has increased its headcount by 45 percent since its previous funding round in April 2020, and significantly increased its on-the-ground global presence with the opening of service centers in new locations, including San Francisco, Philadelphia, Seoul, Rome, Toronto, Tokyo, Seoul, and Ireland.
Source: https://www.privateequitywire.co.uk/2021/10/11/307412/skycell-raises-usd35m-series-c-funding